![]() |
|
|
Vol. 286, Issue 2, 635-642, August 1998
Albert Einstein College of Medicine, Bronx, New York
| |
Abstract |
|---|
|
|
|---|
Endothelin-1 (ET-1) is an important modulator of vasomotor tone that is
thought to participate in the etiology of cardiovascular disease by
virtue of its ability to amplify the contractile responses of vascular
smooth muscle cells to the effects of other vasoactive agents. Despite
this fact, few studies have quantitated the expected contribution of
ET-1 to the enhanced contractile responses elicited in the presence of
another spasmogen. As a first step in this direction, ET-1 and
phenylephrine (PE) were used to evaluate the effects of co-activation
of the ETA/B or alpha-1 adrenergic
receptors, respectively, on contractile responses in isolated rings of
rabbit aorta, mesenteric and femoral artery, or strips of corporal
tissue. Cumulative steady-state concentration-response curves (CRCs)
were constructed to PE alone before the construction of a CRC to ET-1 alone, or a mixture of PE and ET-1 using a previously described drug
concentration paradigm. Computer fits of the logistic equation to CRC
data revealed that in all vascular tissues examined, the partial
substitution of PE with ET-1 was associated with a significant vessel-dependent
3- to 30-fold leftward shift in the CRC (P < .01, Student's t test for paired samples), as judged by
a significant increase in the pEC50 (negative logarithm of
the concentration of drug that elicits one-half of the calculated
maximal effect), in the absence of any detectable effect on the
calculated maximal contractile response (Emax) or the slope
factor (
). A theoretical CRC constructed using the Pöch and
Holzmann method for equiactive substitution demonstrated that the
responses to mixtures of PE and ET-1 were often the result of simple
additivity of agonist effects in these preparations, and thus, were
"expected" based on detailed knowledge of the individual effects of
these two agonists. Regardless of the precision of the Poch and
Holzmann CRC in predicting the effects of this drug mixture in these
vascular tissues, comparison of the "expected" contractile response
with the "observed" response represents an important first step
toward establishing a more uniform nomenclature for describing the
physiological/pathophysiological effects of mixtures of drugs on
diverse vasculature.
| |
Introduction |
|---|
|
|
|---|
The
contractile state of smooth muscle cells in the vascular wall is
determined by a diverse array of neurotransmitters, neuromodulators and
hormones. Clearly, release of norepinephrine from sympathetic adrenergic varicosities plays a primary role in the regulation of
vasomotor tone. However, the effects of sympathetic neurotransmission on vascular smooth muscle tone are further modified by the presence of
many vasoactive substances released from the underlying endothelium. Perhaps chief among this diverse class of endothelial-derived vasoactive substances is the constrictor peptide ET-1 (Yanagisawa et al., 1988
; Luscher and Noll, 1995
; Maguire and Davenport,
1995
; Ohlstein et al., 1995
). In fact, ET-1 is generally
regarded as the most potent circulating vasoconstrictor (Relavic and
Burnstock, 1993
; Ohlstein et al., 1995
; Cesari et
al., 1996
; Tamirisa et al., 1997
), and moreover,
several reports have documented that ET-1 is capable of amplifying the
contractile response to diverse vasoactive compounds (Nakayama et
al., 1991
; Henrion and Laher, 1993
; Consigny, 1990
; Sudjarwo
et al., 1995
).
Taken together, such observations suggest that ET-1 is likely to play a
significant role in cardiovascular physiology and disease, by virtue of
its ability to elicit marked alterations in vascular smooth muscle tone
even in the face of relatively subtle alterations in its plasma
concentration. Consistent with this supposition, elevated plasma levels
of ET-1 have been reported to attend cardiovascular disease (Pernow and
Wang, 1997
; Tamirisa et al., 1997
; Cesari et al.,
1996
; Shichiri et al., 1990
). However, despite the potential
physiological/pathophysiological significance of these established
facts, few studies have attempted to rigorously quantitate the
"expected" contribution of ET-1 to the contractile responses
elicited in the presence of another spasmogen(s). Such quantitative
studies are clearly a prerequisite to elucidating physiological or
pathophysiological mechanisms of ET-1-induced alterations in vascular
smooth muscle tone.
As a first step in this direction, the goal of this investigation was
to characterize steady-state contractile responses elicited by PE-
(phenylephrine) and ET-1-induced activation of the alpha-1 adrenergic and ETA/B receptors, respectively, in
physiologically diverse vasculature. To this end, we utilized a
previously described drug concentration paradigm (Christ et
al., 1990
; Christ and Jean-Jacques 1991
; Kim et al.,
1995
) to examine the effects of the co-administration of PE and ET-1 on
steady-state contractile responses in rings of rabbit aorta, mesenteric
artery and femoral artery, as well as corporal tissue strips.
Comparisons were made between the expected CRC for simple additivity of
agonist effects constructed using the Poch and Holzmann (1980)
method
of equiactive substitution, and the actual CRCs observed for mixtures
of PE and ET-1. In short, these studies documented that the contractile
responses elicited in physiologically diverse rabbit vasculature by
mixtures of PE and ET-1 were often largely those "expected" based
on detailed knowledge of their individual actions.
| |
Materials and Methods |
|---|
|
|
|---|
Vessel collection.
The thoracic aorta (6-8 mm strips), the
superior mesenteric artery (3 mm), the femoral (5 mm) artery and the
corpus cavernosum (3x3x10 mm strips) were excised from a total of 13 male New Zealand white rabbits (3-3.5 kg) obtained from Charles River
Laboratories, St. Constant, Quebec, Canada. Animals were sacrificed by
CO2 asphyxiation and tissues were generally
harvested the day prior to the experiment. Importantly, as previously
reported for rabbit aorta (Christ et al., 1990
), preliminary
studies documented that all of the rabbit vascular tissues used in
these studies could also be stored overnight at room temperature in
Kreb's buffer, without any detectable loss of viability or change in
sensitivity to agonist administration (Christ G. and Gondré M.,
unpublished observations). All loosely adhering fat and connective
tissue were removed from the otherwise adventitia-intact ring
preparations of each vessel.
Corporal tissue collection. The rabbit's penis was removed by an incision at its base near the pubic symphysis and transferred into fresh buffer where it was cleaned of all loosely adhering connective tissue and skeletal muscle on the exterior of the tunica albuginea. The organ was bisected and carefully slit with a scalpel on either side to expose the surfaces of the corporal tissue. The two corporal strips were then removed and cut into sections of equal length.
Tissue pretreatment. All tissues were mounted onto the appropriate hooks and allowed to equilibrate for 1.5 hr at 37°C in a 20 ml organ bath chamber containing Krebs-Henseleit buffer of the following composition (in mM): (NaCl, 124; KCl, 5; MgSO4, 1.3; CaCl2, 2.5; NaH2PO4, 0.6; NaHCO3, 25; and glucose, 11, maintained at a constant pH of 7.4 ± 0.1. Tissues were continuously bubbled with a 95% O2-5% CO2 mixture, and buffer was replaced at 20-min intervals. After tissues had stabilized at 2 g of baseline tension, they were primed by the addition of 3 µM PE to the organ bath. Tissues were then washed and the response to PE was reelicited. This pretreatment protocol reduces the variability of tissue responses to repeated agonist administration (i.e., there are no time-dependent changes in the PE-induced steady-state response over the time course of these experiments). The absence of a relaxation response to carbachol (1 µM) administered during a steady-state contractile response to PE (3 µM) was utilized to confirm the absence of a functional endothelium. Tissue activity was measured isometrically with a FT-03 force transducer and recorded on a Grass model 7E or 7F Polygraph. ET-1 and L-PE were purchased from Sigma Chemical Co., St. Louis, MO.
Construction of CRCs. CRCs were constructed for each specimen by the cumulative addition of drug at half-log increments in the presence of indomethacin. Indomethacin had no effect on the measured tissue response to PE or ET-1, but reduced occasional oscillations of tissue during construction of the steady-state CRCs.
Because preliminary studies affirmed the presence of long-lasting and slowly reversible contractions characteristic of ET-1-induced responses in all preparations studied, CRCs to PE alone, ET-1 alone and mixtures of PE and ET-1 could not all be constructed on the same tissue. Thus, no more than two CRCs were ever performed on the same specimen. More specifically, the experimental paradigm was as follows: a PE CRC was performed on every tissue immediately prior to either a FMR (see below) CRC or an ET-1 CRC. This experimental design allowed each tissue to serve as its own control for the purposes of statistical analysis. This seems a reasonable research strategy in light of the fact that preliminary studies conducted on all four vascular tissues revealed that the logistic parameter estimates for the ET-1 CRC were the same regardless of whether or not PE CRC was performed on the same tissue. All CRCs were constructed at half-log increments, with a minimum of 10 to 12 points.Construction of the FMR CRC.
A previously described method
was used for the construction of the FMR CRCs (Christ et
al., 1990
, Christ and Jean-Jacques, 1991
). Briefly, cumulative
CRCs were constructed at half-log increments such that for any given
total molar drug concentration in the CRC, a fixed ratio was selected
for the PE:ET-1 mixture. For these experiments the ratio of the two
drugs in the mixture was always 80:20 (PE:ET-1); please note that
preliminary studies showed that similar results were also obtained with
other FMRs (i.e., 90:10 or 70:30). Furthermore, the
rationale for using only FMRs in which the concentration of PE was
higher than that of ET-1 was related to the following: the
EC50 for PE was always 1 to 2 orders of magnitude
greater than the EC50 for ET-1 on each
preparation. Thus, we could only test FMRs in which the concentration
of PE was more than that for ET-1. That is, PE:ET-1 FMRs less than 1 would have resulted in such low occupancies of the alpha-1
adrenergic receptor, for so much of the CRC, that it would have been
impractical to accurately evaluate the contribution of PE to the
response. Finally, to simplify the graphical comparison of control and
mixture CRCs, all displayed concentrations represent either the
concentration of PE alone, ET-1 alone or the mixture of PE + ET-1.
Construction of equiactive CRCs.
The equiactive CRC was
constructed in accordance with the method of Pöch and Holzmann
(1980)
as previously described (Christ and Jean-Jacques, 1991
, Christ
et al., 1990
; Kim et al., 1996
). At each point on
the observed FMR, the response produced by a known concentration of
ET-1 was calculated from the logistic equation that describes the ET-1
CRC. The concentration of PE necessary to produce this same response
(equiactive) was then similarly calculated, and the concentration of
ET-1 at every point of the FMR was replaced by an equiactive
concentration of PE. The response produced by the sum of the two PE
concentrations was calculated from the logistic equation and plotted
vs. the total concentration for the corresponding FMR. For
example, let us examine the 80% PE: 20% ET-1 (PE:ET-1) FMR CRC on a
rabbit mesenteric ring. In this case, a 10 nM concentration on the
80:20 (PE:ET-1) FMR contains 2 nM ET-1 and 8 nM PE. 2 nM ET-1 produces
the same effect that PE produces at a concentration of 82 nM. Thus, the
response to 90 nM (i.e., 8 + 82 nM) PE was plotted as the
Pöch and Holzmann prediction of the response on the 10 nM FMR.
This value represents the anticipated response if the contraction were
a result of simple additivity.
Data analysis. The magnitude of the contractile responses were empirically determined from the chart recorder and computer fit using the RS/1 software package (BBN Software, Cambridge, MA) on a Gateway 2000-486DX/33 computer to the general logistic equation:
|
is the
slope index of the CRC.
Statistical analysis. Statistical comparisons were made using the Statview II software program on a MacIntosh Quadra 800. The EC50 values were expressed as the geometric mean ± S.E.M. (i.e., pEC50: negative logarithm of the EC50), whereas all other parameters were expressed as their arithmetic mean ± S.E.M. A Student's t test for paired samples was used to compare Emax, EC50 and slope factor values for PE, ET-1, and PE + ET-1 (i.e., FMR) CRCs performed on the same tissue strip; P < .05 was considered statistically significant in all cases.
| |
Results |
|---|
|
|
|---|
Analysis of PE and ET-1 CRCs. Cumulative CRCs were constructed for steady-state contractile responses elicited by PE alone and ET-1 alone on rings of rabbit aorta, femoral artery and mesenteric artery, as well as corporal tissue strips. Table 1 summarizes the calculated mean Emax, pEC50 and slope factor values derived from computer fits of the logistic equation to these CRC data. As shown, statistical analysis revealed significant differences in the location of the PE and ET-1 CRCs, as reflected by the significantly different pEC50 values (P < .0001; Student's t test for paired samples) for ET-1 when compared to PE in all four vascular tissues studied. Additionally, significant differences were detected between PE and ET-1 in the calculated Emax values for aortic and mesenteric rings, as well as corporal tissue strips (P < .01 in all cases; Student's t test for paired samples), but not for the femoral rings (P > .05). There was no detectable difference in the slope factor value that describes the PE and ET-1 CRCs in any of the preparations studied. The relationship among the ET-1, PE and 80:20 FMR CRCs are depicted in the representative examples illustrated in figure 1.
|
|
Comparison of the PE and 80:20 (PE:ET-1) FMR CRCs.
CRCs were
also constructed for PE before performing another CRC on the same
isolated tissue preparation for a mixture of PE and ET-1
using a FMR protocol (see "Materials and Methods"). In this
fashion, PE and 80:20 (PE:ET-1) FMR CRCs were constructed for all four
vascular tissues, once again permitting each tissue to serve as its own
control. Mean logistic parameter estimates for the PE alone and 80:20
FMR CRCs in each isolated vascular tissue are summarized in table
2, and representative examples are
graphically depicted in figure 2. In
short, the partial substitution of ET-1 for PE, revealed the following
for the 80:20 FMR: 1) an
3- to 28-fold leftward shift in the
pEC50 (P < .05, Student's t
test for paired samples), in the absence of any detectable changes in
either the Emax or slope factor values.
|
|
Construction of the expected CRC for simple additivity of agonist
effects.
The Poch and Holzmann method (1980)
of equiactive
substitution was utilized to further explore the nature of the observed leftward shift in the PE CRC in the presence of ET-1. As illustrated in
figure 3, some discrepancy was observed
in the point estimates that describe the mean response levels for the
80:20 FMR and the response expected based on simple additivity of
agonist effects, respectively. However, despite this apparent
discrepancy, the expected CRC for simple additivity of agonist effects
fell largely within the 95% confidence interval for the mean 80:20 FMR
in each of the vascular tissues examined. This fact indicates that
simple additivity of agonist effects seems to provide a reasonable
description of the effects of this drug mixture on the steady-state
contractile responses observed in these vascular tissues (fig. 3).
|
| |
Discussion |
|---|
|
|
|---|
The potent and long-lasting nature of the ET-1-induced contractile
response in vasculature has led many investigators to propose that ET-1
is likely to play a significant role in cardiovascular physiology and
disease (Yang et al., 1990
; Consigny, 1990
; Ohlstein et al., 1995
; Tamirisi et al., 1997
). In fact, in
the complex hormonal milieu present in vivo, it is
conceivable that ET-1 could elicit quite marked alterations in vascular
smooth muscle tone even in the face of relatively subtle alterations in
its plasma concentration. Consistent with such a hypothesis, several
reports have shown that threshold or near threshold concentrations of ET-1 potentiate contractile responses to other vasoactive agents (Nakayama et al., 1991
; Henrion and Laher, 1993
; Consigny,
1990
; Yang et al., 1990
). However, insufficient information
was provided in these seminal studies to determine whether or not the
observed increase in the magnitude of the contraction was at all
"expected." Such considerations are especially important when
utilizing threshold or near threshold drug concentrations, because of
the marked percent variability in tissue response observed near
threshold. Moreover, despite the potential importance of these
observations to vascular physiology and disease, to date, there has
been no systematic and rigorous investigation into the "expected"
contribution of ET-1 to the enhanced contractile response elicited in
the presence of another vasoactive agent. As a first step in this
direction, the goal of these studies was to evaluate contractile
responses elicited during coactivation of the ET and alpha-1
adrenergic receptors using a previously described drug concentration
paradigm.
To do so we chose to use a previously described FMR protocol, rather
than the single concentration method originally used by Poch and
Holzmann. As discussed elsewhere (Christ et al., 1990
) the
FMR method conveys a distinct advantage for evaluating the potential
physiological relevance of the interaction of a drug mixture. That is,
with the one concentration method, as originally described by Poch and
Holzmann, one is evaluating the effects of increasing the concentration
of one drug in the presence of the same concentration
(i.e., stimulus) of a second drug. The observed effects are
thus very dependent on the fixed concentration of drug that is
initially chosen; this can be especially critical when one is
evaluating "threshold" effects. In contrast, the FMR ratio method
evaluates the interaction between two drugs at a variety of different
concentrations of each, throughout much of their respective
CRCs. Thus, as long as the EC50 values for the two drugs of interest are within 1 to 2 orders of magnitude, the latter
allows a more complete evaluation of the nature of the interaction
between a drug mixture, from threshold to maximally active
concentrations of the two drugs of interest. Of course it should be
pointed out that the systematic method of describing/evaluating simple
additivity of agonist effects as originally proposed by Poch and
Holzmann applies regardless of the exact protocol used to evaluate the
drug mixture.
In this regard, a detailed pharmacological analysis of the CRCs that
describe PE- and ET-1-induced steady-state contractile responses in
each tissue was a prerequisite to evaluation of the "expected"
effects of a mixture of these same drugs. Logistic analysis revealed an
4- to 5-fold range of values for both the calculated
Emax and pEC50 parameter
estimates for the PE and ET-1 CRCs, respectively, among these four
distinct isolated vascular tissues (see fig. 1). In all tissues, the
location (i.e., EC50) of the ET-1 CRC
was significantly to the left of the PE CRC, and with the exception of
the femoral artery, the calculated Emax value for
PE-induced contractions was significantly greater than that for
ET-1-induced contractions (table 1).
Having established the characteristics of the PE- and ET-1-induced steady-state CRCs in each preparation, a previously described FMR protocol was used to study steady-state contractile responses elicited by a single mixture of these two compounds [i.e., the 80:20 (PE:ET-1 FMR); see "Materials and Methods" for details]. In short, construction of CRCs to PE alone, as well as mixtures of PE and ET-1, on the same tissue from the same animal, revealed an apparently vessel-dependent 3- to 22-fold leftward shift of the EC50; with no detectable effect on Emax or slope factor (fig. 2; table 2).
To evaluate the nature of the leftward shift in the FMR CRC for each
vascular tissue type, the 80:20 FMR CRC was compared to the CRC for
simple additivity of agonist effects, as constructed using the Poch and
Holzmann (1980)
method of equiactive substitution (fig. 3). Even though
the average point estimate for the Pöch and Holzmann CRC did not
necessarily directly coincide with the corresponding mean value for the
80:20 FMR, for the most part, the expected CRC for simple additivity of
agonist effects (fig. 3) did fall within the 95% C.I. for the 80:20
FMR CRC on each preparation. As might be expected, the discrepancies
between the 95% C.I. for the 80:20 FMR and the Poch and Holzmann CRC
mostly occurred on the linear portion of the FMR CRC (see fig. 3a, c and d). The deviation of the Pöch and Holzmann CRC from the 95% C.I. for the 80:20 FMR was more frequently under-additive (fig. 3a and
d) than over-additive (fig. 3c). Thus, overall it appears that the
steady-state contractile response to mixtures of PE and ET-1 in diverse
rabbit vasculature is reasonably well codified by the Pöch and
Holzmann (1980)
method of equiactive substitution.
Certainly PE and ET-1 can each elicit contractile responses after
activation of more than one alpha-1 adrenergic
(
1a, b) (Pepperl and Regan, 1994
) or ET
(ETA/B) (Seo and Luscher, 1995
; Hay et
al., 1996
; Moreland et al., 1994
; Ladouceur et
al., 1993
) receptor subtype. Despite this fact, no attempt was
made in these initial studies to delineate either the particular
receptor subtype(s) present or their relative contributions to the
actions of PE and ET-1 in these vascular tissues. This seems reasonable
given the fact that the pharmacological analysis applied here
[i.e., the Pöch and Holzmann (1980)
additivity
analysis] is independent of such considerations, and moreover, that
the focussed aim of these initial studies was solely to compare the
"expected" effects of this drug mixture to the "observed"
effects in these physiologically diverse vascular tissues.
The conclusions of this report are similar to that of a previous study
in isolated human corporal tissue strips (Kim et al., 1996
).
In that study, Kim et al., (1996)
reported that FMR CRCs to
PE and ET-1 was also largely predicted by the Pöch and Holzmann (1980)
method of equiactive substitution. As such, simple additivity of
agonist effects seems to be characteristic of steady-state contractile
responses to mixtures of PE and ET-1 in diverse rabbit vasculature, as
well as the specialized vascular tissue of the human corpus cavernosum.
However, even though the Pöch and Holzmann CRC was also
sufficient to describe steady-state contractile responses elicited on
rat aortic rings by a distinct drug mixture (i.e., PE and
5-HT), it cannot be assumed that simple additivity reflects a general
principle governing normal vascular pharmacology. As a case in point,
previous studies conducted in rabbit aorta demonstrated that for
mixtures of PE and 5-HT, the resulting FMR CRC was always more than
additive on the linear portion of the CRC (Christ et al.,
1990
). That is, in the same vascular tissue, the rabbit aorta, the
location of the Pöch and Holzmann (1980)
CRC indicates that the
PE:ET-1 FMR CRC is largely additive or under-additive (see fig. 3),
although the PE:5-HT FMR CRC is actually over-additive (Christ et
al., 1990
).
Such observations clearly demonstrate that even when vasoactive agents
act through the same putative effector pathways (i.e., activation of the
1-adrenergic (Timmermans and
Thoolen, 1987
), ETA/B (Goto et al.,
1989
; Griendling et al., 1989
; Nambi et al., 1995
; Tamirisa et al., 1997
) and 5-HT2
(Feniuk and Humphrey, 1987
) receptor subtypes are all thought to result
in contractile responses that are mediated, in large part, by
activation of the inositol trisphosphate, diacylglycerol and protein
kinase C pathway, the resultant contractile responses are still not
necessarily predictable. These results are not surprising when one
considers the manifold events that occur between receptor activation
and tension development in isolated vascular tissues. In fact, although
signal transduction pathways for activation of distinct membrane
receptors may have considerable overlap [i.e., PE and 5-HT
(Christ et al., 1990
)], they may not be identical. As such,
it is conceivable that subtle dichotomies in the signal transduction
pathways mediated by activation of distinct membrane receptors could
well lead to "unexpected" contractile responses to one drug mixture
(i.e., PE and 5-HT in rabbit aorta), although simultaneously
eliciting "expected," i.e., additive responses to
another drug mixture (i.e., PE and ET-1 as reported in
rabbit aorta) in the same vessel. For example, as described elsewhere
(Kenakin, 1997
; Kenakin and Morgan, 1989
; Weiss et al.,
1996
), differences in the observed contractile responses elicited by
different drug mixtures might result when distinct membrane receptors
activate either more than one G protein, or possibly, a slightly
different complement of G proteins.
In fact, therein lies the main importance of the knowledge gained from
the current studies. That is, application of the Poch and Holzmann
(1980)
method of equiactive substitution provides a critical conceptual
framework for making comparisons between the "expected" and
"observed" effects of mixtures of physiologically relevant agonists
on the same or distinct vascular tissues. Clearly it remains to be
determined what impact age or disease might have on the relationship
between the "expected" and "observed" responses of these
vascular tissues to PE and ET-1.
Undoubtedly, the in vitro experimental analysis reported here greatly oversimplifies the in vivo situation. Nonetheless, these initial observations do provide a general background for beginning to address such complex and physiologically relevant issues. Future studies in vasculature from aged or diseased animals is the next logical step in identifying the boundary conditions for the relevance of this type of analysis to the understanding of normal vascular physiology in vivo, as well as perhaps identifying some mechanistic aspects of vascular disease.
| |
Acknowledgments |
|---|
The authors are grateful for the technical assistance of Dr. Daniel Kim.
| |
Footnotes |
|---|
Accepted for publication April 13, 1998.
Received for publication October 10, 1997.
1 This work was supported in part by United States Public Health Service Grant DK46379.
Send reprint requests to: Dr. George J. Christ, Associate Professor, Ben Marden Distinguished Scholar in Urology, Laboratory of Molecular and Integrative Urology, Room 716S, Forchheimer Building, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, NY 10461.
| |
Abbreviations |
|---|
CRC, concentration response curves; FMR, fixed molar ratio; PE, phenylephrine; ET-1, endothelin-1.
| |
References |
|---|
|
|
|---|
1-adrenergic and 5-HT2 receptors in isolated rat aorta.
J Pharmacol Exp Ther
256:
553-561
1-adrenergic agonist on human corpus cavernosum smooth muscle.
Int J Impotence Res
8:
17-24[Medline].This article has been cited by other articles:
![]() |
S. Filippi, M. Marini, G.B. Vannelli, C. Crescioli, S. Granchi, L. Vignozzi, M. Luconi, P. Ferruzzi, A. Morelli, G. Forti, et al. Effects of hypoxia on endothelin-1 sensitivity in the corpus cavernosum Mol. Hum. Reprod., December 1, 2003; 9(12): 765 - 774. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. J. Wingard, S. Husain, J. Williams, and S. James RhoA-Rho kinase mediates synergistic ET-1 and phenylephrine contraction of rat corpus cavernosum Am J Physiol Regulatory Integrative Comp Physiol, November 1, 2003; 285(5): R1145 - R1152. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. F. Lue Erectile Dysfunction N. Engl. J. Med., June 15, 2000; 342(24): 1802 - 1813. [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||